GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » Equity-to-Asset

GNMLF (Genomma Lab InternacionalB de CV) Equity-to-Asset : 0.47 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genomma Lab InternacionalB de CV's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $566.4 Mil. Genomma Lab InternacionalB de CV's Total Assets for the quarter that ended in Sep. 2024 was $1,193.9 Mil. Therefore, Genomma Lab InternacionalB de CV's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.47.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Equity-to-Asset or its related term are showing as below:

GNMLF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38   Med: 0.44   Max: 0.53
Current: 0.47

During the past 13 years, the highest Equity to Asset Ratio of Genomma Lab InternacionalB de CV was 0.53. The lowest was 0.38. And the median was 0.44.

GNMLF's Equity-to-Asset is ranked worse than
66.54% of 1043 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs GNMLF: 0.47

Genomma Lab InternacionalB de CV Equity-to-Asset Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Equity-to-Asset Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.41 0.47 0.47 0.46

Genomma Lab InternacionalB de CV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.46 0.46 0.48 0.47

Competitive Comparison of Genomma Lab InternacionalB de CV's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Equity-to-Asset falls into.



Genomma Lab InternacionalB de CV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Genomma Lab InternacionalB de CV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=556.216/1221.762
=0.46

Genomma Lab InternacionalB de CV's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=566.423/1193.9
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Genomma Lab InternacionalB de CV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.